Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000077.xml
Download PDF
Semin Thromb Hemost 2016; 42(05): 483-497
DOI: 10.1055/s-0036-1579641
DOI: 10.1055/s-0036-1579641
Type 2M and Type 2A von Willebrand Disease: Similar but Different
Further Information
Publication History
Publication Date:
05 May 2016 (online)
Abstract
Analogous to the differentiation between hemophilia A and B, respectively, reflecting deficiency in factor VIII (FVIII) and FIX, and increasing being recognized as reflecting clinically different disorders, types 2A and 2M von Willebrand disease (VWD) can also be shown to express both similarities and differences in their prevalence, genetic defects, laboratory test results, clinical features, and treatment responses. In this narrative review, we explore these two “subtypes” of type 2 VWD, identifying parallels and dissimilarities in various aspects of their presentation to clinicians and to scientists/laboratories. This differential will become increasingly important as we strive to provide personalized approaches to future management of patients with VWD, particularly in the emerging landscape of recombinant von Willebrand factor.
-
References
- 1 Santagostino E, Fasulo MR. Hemophilia A and hemophilia B: different types of diseases?. Semin Thromb Hemost 2013; 39 (7) 697-701
- 2 Sadler JE, Budde U, Eikenboom JC , et al; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4 (10) 2103-2114
- 3 Nichols WL, Hultin MB, James AH , et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14 (2) 171-232
- 4 Favaloro EJ. Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. Semin Thromb Hemost 2011; 37 (5) 440-455
- 5 Favaloro EJ. Diagnosing von Willebrand disease: a short history of laboratory milestones and innovations, plus current status, challenges, and solutions. Semin Thromb Hemost 2014; 40 (5) 551-570
- 6 Ng C, Motto DG, Di Paola J. Diagnostic approach to von Willebrand disease. Blood 2015; 125 (13) 2029-2037
- 7 Lillicrap D. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Hematology (Am Soc Hematol Educ Program) 2013; 2013 (13) 254-260
- 8 Favaloro EJ, Bodó I, Israels SJ, Brown SA. von Willebrand disease and platelet disorders. Haemophilia 2014; 20 (Suppl. 04) 59-64
- 9 Flood VH. Perils, problems, and progress in laboratory diagnosis of von Willebrand disease. Semin Thromb Hemost 2014; 40 (1) 41-48
- 10 Yee A, Kretz CA. Von Willebrand factor: form for function. Semin Thromb Hemost 2014; 40 (1) 17-27
- 11 Peyvandi F, Garagiola I, Baronciani L. Role of von Willebrand factor in the haemostasis. Blood Transfus 2011; 9 (Suppl. 02) s3-s8
- 12 Jaffe EA, Hoyer LW, Nachman RL. Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci U S A 1974; 71 (5) 1906-1909
- 13 Sporn LA, Chavin SI, Marder VJ, Wagner DD. Biosynthesis of von Willebrand protein by human megakaryocytes. J Clin Invest 1985; 76 (3) 1102-1106
- 14 Favaloro EJ, Bonar R, Favaloro J, Koutts J. Diagnosis and management of von Willebrand disease in Australia. Semin Thromb Hemost 2011; 37 (5) 542-554
- 15 Federici AB, Bucciarelli P, Castaman G , et al. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. Semin Thromb Hemost 2011; 37 (5) 511-521
- 16 Rodgers SE, Lloyd JV, Mangos HM, Duncan EM, McRae SJ. Diagnosis and management of adult patients with von Willebrand disease in South Australia. Semin Thromb Hemost 2011; 37 (5) 535-541
- 17 Iorio A, Oliovecchio E, Morfini M, Mannucci PM ; Association of Italian Hemophilia Centres Directors. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. Haemophilia 2008; 14 (3) 444-453
- 18 Penas N, Pérez-Rodríguez A, Torea JH , et al. von Willebrand disease R1374C: type 2A or 2M? A challenge to the revised classification. High frequency in the northwest of Spain (Galicia). Am J Hematol 2005; 80 (3) 188-196
- 19 Riddell AF, Jenkins PV, Nitu-Whalley IC, McCraw AH, Lee CA, Brown SA. Use of the collagen-binding assay for von Willebrand factor in the analysis of type 2M von Willebrand disease: a comparison with the ristocetin cofactor assay. Br J Haematol 2002; 116 (1) 187-192
- 20 Goodeve A, Eikenboom J, Castaman G , et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007; 109 (1) 112-121
- 21 James PD, Paterson AD, Notley C , et al; ASSOCIATION OF HEMOPHILIA CLINIC DIRECTORS OF CANADA. Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study. J Thromb Haemost 2006; 4 (4) 783-792
- 22 James PD, Notley C, Hegadorn C , et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007; 109 (1) 145-154
- 23 James PD, Notley C, Hegadorn C , et al; Association of Hemophilia Clinic Directors of Canada. Challenges in defining type 2M von Willebrand disease: results from a Canadian cohort study. J Thromb Haemost 2007; 5 (9) 1914-1922
- 24 Cumming A, Grundy P, Keeney S , et al; UK Haemophilia Centre Doctors' Organisation. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost 2006; 96 (5) 630-641
- 25 Laffan M, Brown SA, Collins PW , et al. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004; 10 (3) 199-217
- 26 Favaloro EJ, Bonar RA, Meiring M , et al. Evaluating errors in the laboratory identification of von Willebrand disease in the real world. Thromb Res 2014; 134 (2) 393-403
- 27 Favaloro EJ, Bonar RA, Mohammed S , et al. Type 2M von Willebrand disease – more often misidentified than correctly identified. Haemophilia 2016; doi: 10.1111/hae.12903
- 28 Arbelaez A, Niemann J, Freney R , et al. “Bleeding in the jungle”. Am J Hematol 2015; 90 (9) 843-846
- 29 Favaloro EJ, Bonar R, Meiring M, Street A, Marsden K ; RCPA QAP in Haematology. 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD. Thromb Haemost 2007; 98 (2) 346-358
- 30 The online von Willebrand disease (VWD) database . Available at: https://grenada.lumc.nl/LOVD2/VWF/variants.php?action=search_all . Accessed November 22, 2015
- 31 Favaloro EJ, Krigstein M, Koutts J, Brighton T, Lindeman R. Genetic testing for the diagnosis of von Willebrand disease: benefits and limitations. J Coagul Disord 2010; 2: 37-47
- 32 Favaloro EJ. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin?. Semin Thromb Hemost 2008; 34 (1) 113-127
- 33 Federici AB, Mannucci PM, Castaman G , et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 2009; 113 (3) 526-534
- 34 Favaloro EJ, Mohammed S, Koutts J. Identification and prevalence of von Willebrand disease type 2N (Normandy) in Australia. Blood Coagul Fibrinolysis 2009; 20 (8) 706-714
- 35 Favaloro EJ, Plebani M, Lippi G. Regulation in hemostasis and thrombosis: part I-in vitro diagnostics. Semin Thromb Hemost 2013; 39 (3) 235-249
- 36 Chandler WL, Peerschke EIB, Castellone DD, Meijer P ; NASCOLA Proficiency Testing Committee. Von Willebrand factor assay proficiency testing. The North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol 2011; 135 (6) 862-869
- 37 Meijer P, Haverkate F. An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. Semin Thromb Hemost 2006; 32 (5) 485-491
- 38 Favaloro EJ. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD): a rebuttal. J Thromb Haemost 2008; 6 (11) 1999-2001 , author reply 2002–2003
- 39 Adcock DM, Bethel M, Valcour A. Diagnosing von Willebrand disease: a large reference laboratory's perspective. Semin Thromb Hemost 2006; 32 (5) 472-479
- 40 Flood VH, Gill JC, Friedman KD , et al; Zimmerman Program Investigators. Collagen binding provides a sensitive screen for variant von Willebrand disease. Clin Chem 2013; 59 (4) 684-691
- 41 Favaloro EJ, Grispo L, Exner T, Koutts J. Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and type II, von Willebrand's disease. Blood Coagul Fibrinolysis 1991; 2 (2) 285-291
- 42 Favaloro EJ. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost 2007; 33 (8) 727-744
- 43 Favaloro EJ, Dean M, Grispo L, Exner T, Koutts J. von Willebrand's disease: use of collagen binding assay provides potential improvement to laboratory monitoring of desmopressin (DDAVP) therapy. Am J Hematol 1994; 45 (3) 205-211
- 44 Favaloro EJ, Kershaw G, Bukuya M, Hertzberg M, Koutts J. Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA-100 and vWF:CBA as combined diagnostic strategies. Haemophilia 2001; 7 (2) 180-189
- 45 Favaloro EJ, Mohammed S. Towards improved diagnosis of von Willebrand disease: comparative evaluations of several automated von Willebrand factor antigen and activity assays. Thromb Res 2014; 134 (6) 1292-1300
- 46 Favaloro EJ, Mohammed S. Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease. Thromb Res 2015; (e-pub ahead of print). doi:10.1016/j.thromres.2015.12.010
- 47 Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost 2000; 83 (1) 127-135
- 48 Favaloro EJ. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease. Thromb Haemost 2010; 104 (5) 1009-1021
- 49 Castaman G, Federici AB, Tosetto A , et al. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost 2012; 10 (4) 632-638
- 50 Rodeghiero F. Von Willebrand disease: pathogenesis and management. Thromb Res 2013; 131 (Suppl. 01) S47-S50
- 51 Tosetto A, Castaman G. How I treat type 2 variant forms of von Willebrand disease. Blood 2015; 125 (6) 907-914
- 52 Curnow J, Pasalic L, Favaloro E. Treatment of von Willebrand disease. Semin Thromb Hemost 2016; 42 (2) 133-146
- 53 Favaloro EJ, Franchini M, Lippi G. Biological therapies for von Willebrand disease. Expert Opin Biol Ther 2012; 12 (5) 551-564
- 54 Mannucci PM, Kempton C, Millar C , et al; rVWF Ad Hoc Study Group. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood 2013; 122 (5) 648-657
- 55 Gill JC, Castaman G, Windyga J , et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood 2015; 126 (17) 2038-2046
- 56 Saccullo G, Makris M. Prophylaxis in von Willebrand disease: coming of age?. Semin Thromb Hemost 2016; 42 (5) 498-506
- 57 Kingman CE, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG 2004; 111 (12) 1425-1428
- 58 Boey JP, Hahn U, Sagheer S, McRae SJ. Thalidomide in angiodysplasia-related bleeding. Intern Med J 2015; 45 (9) 972-976
- 59 Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev 2010; 24 (3) 123-134
- 60 Lyons SE, Bruck ME, Bowie EJW, Ginsburg D. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem 1992; 267 (7) 4424-4430
- 61 Rayes J, Hommais A, Legendre P , et al. Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13. J Thromb Haemost 2007; 5 (2) 321-328
- 62 Sadler JE. Aortic stenosis, von Willebrand factor, and bleeding. N Engl J Med 2003; 349 (4) 323-325
- 63 Kunicki TJ, Baronciani L, Canciani MT , et al. An association of candidate gene haplotypes and bleeding severity in von Willebrand disease type 2A, 2B, and 2M pedigrees. J Thromb Haemost 2006; 4 (1) 137-147
- 64 Favaloro EJ, Bonar R, Marsden K. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients: a rebuttal. J Thromb Haemost 2012; 10 (7) 1455-1458 , author reply 1458–1460
- 65 Federici AB, Mazurier C, Berntorp E , et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 2004; 103 (6) 2032-2038
- 66 Favaloro EJ. Towards personalized therapy for von Willebrand disease: future role of recombinant products. Blood Transfus 2016; DOI 10.2450/2016.0258-15